



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 28th Feburary, 2022

“SAY NO TO CORRUPTION”

Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 98th meeting held on 29th October, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No (1)	Brand name (2)	Decision (3)
For Export Facilitation (Local) M/s Brick Laboratories Unani (Pvt.) Ltd., Lahore		
1.	HEPTOLIC DROPS	Deferred for submission of revised Form-3.
2.	HEPTOLIC DROPS	Deferred for submission of revised Form-3.
For Export Facilitation (Local) M/s. Qarshi Industries (Pvt.) Ltd., (E. No. 000414) Plot NO.56/1-4, 82, 82/1, 82/1-A, & 83, Phase 1 & II, Industrial Estate Hattar, District Haripur		
3.	Qarshi'sKasniKARE Capsule	Deferred for provision of monograph lepidium sativam
4.	Qarshi'sObesigone Capsule	Deferred for provision of monograph of Chitosan and pectin
For Export Facilitation (Local) M/s Wilshire Labs (Pvt) Ltd. Lahore		
5.	Wilyte R Sachet	Deferred till finalization of common molecule
M/s Blossom Lab, Pvt, Ltd, Lahore		
6.	Conle-4 Tablet	Deferred for final opportunity for change of brand name
7.	Im-Fit Tablet	Deferred for final opportunity for change of brand name
8.	Obeslime + Tablet	Deferred for final opportunity for change of brand name
9.	Leucovit Tablet	Deferred for final opportunity for change of brand name
10.	Licoright tablet	Deferred for final opportunity for change of brand name
M/S Florex Pharma (Pvt.) Ltd. Mandianwala Stop, 25-Km Jaranwala Road, Sheikhpura (E. No. 01126)		
11.	PRENEX F SACHET	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: The firm applied same formulation with insignificant difference as MALINOX-K Sachet.
12.	AMINOREX CAPSULE	EEC decided to defer the application for enlistment and to give final opportunity for the fulfillment of following deficiencies: <ul style="list-style-type: none"> • Provide monograph of L-ornithine • Revise name of ingredient as per monograph attached.
M/s Moon Star Herbal Laboratory Plot No.86-A, Industrial Area, Hayatabad, Peshawar (E. No. 01128)		
13.	MOON STAR'S SYRUP Golden Alpha Coff	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
14.	MOON STAR'S SYRUP Golden Menso Guard	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
15.	MOON STAR'S CAPSULE GOLDEN JARNIDE-X	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
16.	MOON STAR'S CAPSULE LIKONIL	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.

S.No (1)	Brand name (2)	Decision (3)
17.	MOON STAR'S CAPSULE GOLDEN GYNE CARE	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
18.	MOON STAR'S CAPSULE GOLDEN FRESH BLOOD	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
19.	MOON STAR'S CAPSULE GOLDEN LEAKO SEALER	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
20.	MOON STAR'S GOLDEN KHAMEERA-E-GAOZABAN	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
21.	MOON STAR'S GOLDEN LABOOB-E-KABEER	The EEC decided to defer the application for enlistment and to give final opportunity for the submission of following documents <ul style="list-style-type: none"> • Provide at least three alternate Brand names for the product applied in compliance with the policy approved by EEC for brand name. • The firm applied same formulation with different trade name i.e. MOON STAR'S GOLDEN LABOOB-E-KABEER KHAS UL KHAS, need clarification
22.	MOON STAR'S GOLDEN LABOOB-E-KABEER KHAS UL KHAS	The EEC decided to defer the application for enlistment and to give final opportunity for the submission of following documents <ul style="list-style-type: none"> • The firm applied same formulation with different trade name i.e. MOON STAR'S GOLDEN LABOOB-E-KABEER, need clarification.
23.	MOON STAR'S GOLDEN ANTI-ALERGY SAFOOF	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
24.	MOON STAR'S GOLDEN HYPER OFF SAFOOF	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
<p align="center">M/s Nestro Pharma International, Plot No. 29, Street No. S-2, RCCI Industrial Estate, Rawat (E. No. 01130)</p>		
25.	NESFAIR Capsule	EEC decided to defer the application for enlistment and to give final opportunity for the change of brand name.
<p align="center">M/s. EON PHARMACY, (E. No. 0093) Located at Plot No. A/150, Sector 11-E, New Karachi</p>		
26.	Eon's Arzyme Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> • It is combination product. • According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
27.	Eon's Irocof C & F Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> • It is combination product. • According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required. • Brand name to be change.
28.	Eon's Multi V Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> • It is combination product. • According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required. • Brand name to be change.
29.	Eon's Trimic Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> • It is combination product. • According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required. • Brand name to be change.
30.	Eon's Broncos Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> • It is combination product. • According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required. • Brand name to be change.
31.	Eon's Diaric Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> • It is combination product.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
32.	Eon's Dijirex Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
33.	Eon's Surbeton Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
34.	Eon's Ribavit Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
35.	Eon's Drosecos Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
36.	Eon's Drosecos DM Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required.
37.	Eon's Dizyme Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required. Brand name to be change
38.	Eon's Dizyme-V Syrup	Deferred with final opportunity for the following reasons: <ul style="list-style-type: none"> It is combination product. According to notification F. 4-2/2017-DD(H&OTC) dated 21st April, 2020, documents about company/ firm enlistment and sale invoices including distribution record for last 10 years, required. Brand name to be change
M/s A.R. Nutraceutical Pharma (Pvt) Limited, (E. No. 0074) Plot No. F-4/C, S.I.T.E., Phase-II, Super Highway, Karachi		
39.	ARTHOLEX ADVANCE Tablet	Deferred till finalization of policy regarding common molecules
40.	Fyzinc Syrup	Deferred till the finalization of policy regarding common molecules
M/s MR Enterprises, A-78/1 Shahbaz Town Scheme near Honda Place, Jamshoro Road, Qasimabad Hyderabad agent of M/s Shandong Soocom Animal Remedy Co., Ltd., Xundakang Road No.666 agricultural high & new technology development zone of Jinan, China (Veterinary)		
41.	Multivita WSP	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> COA of active ingredient and finished product is required. Long term stability studies data according to Zone IV-A requirement, mentioning percentage assay of each active ingredient is required. Solo Agency agreement between principal manufacturer and importer i.e. M/s MR Enterprises is required.
42.	Livercare Oral Solution	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term stability studies data according to Zone IV-A requirement, mentioning percentage assay of active ingredient e.g. DL –Methionine and L-Lysine is required. COA of active ingredient and finished product is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Solo Agency agreement between principal manufacturer and importer i.e. M/s MR Enterprises is required.
43.	VitE-SE10 Oral Solution	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> COA of active ingredient and finished product is required. Solo Agency agreement between principal manufacturer and importer i.e. M/s MR Enterprises is required.
M/s Prospect Group (Pvt.) Ltd, 125-Upper Mall, Lahore agent of M/s Nutra Manufacturing, 1050 Woodruff Road, Greenville, SC 29607. Subsidiary of General Nutrition Corporation (GNC), USA (E. No. 00299)		
44.	GNC (INTL) Double Strength Fish Oil Softgel Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Brand Name mentioned on Form 5 is GNC (INTL) Double Strength Fish Oil Softgel Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Double Strength Fish Oil Softgel Capsule, needs clarification. Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.
45.	GNC Vit C 500 Rose Hips Caplets	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Brand Name mentioned on Form 5 is GNC Vit C 500 Rose Hips Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is Vit C 500 Rose Hips Caplets, needs clarification. Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
46.	GNC Isomer E Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Brand Name mentioned on Form 5 is GNC Isomer E Capsule Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Isomer E Capsule, needs clarification. Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
47.	GNC (INTL) Prima C 1000mg Tablet	Deferred with the final opportunity for the provision of following documents: <ul style="list-style-type: none"> Brand Name mentioned on Form 5 is GNC (INTL) Prima C 1000mg Tablet Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Prima C 1000mg Tablet, needs clarification. Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
48.	GNC (INTL) Ginkgo Biloba Plus Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Brand Name mentioned on Form 5 is GNC (INTL) Ginkgo Biloba Plus Tablet Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Ginkgo Biloba Plus Tablet, needs clarification. Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
49.	GNC Kids Eye Health Chewable Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Kids Eye Health Chewable Tablet • Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Kids Eye Health Chewable Tablet, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
50.	GNC Brighten Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Brighten Capsule and brand name given on COA is Skin lightening Pil Vegetable Hard-shell capsule, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Valid and Notarized fee sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
51.	GNC (INTL) DHA 600 Capsule	<p>Deferred with the final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) DHA 600 Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Intl DHA 600, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
52.	GHC Ultra Saw Palmetto Formula Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GHC Ultra Saw Palmetto Formula Capsule • and brand name given on Exhibit A attached copy of Certificate of Free Sale is Ultra Saw Palmetto Formula Capsule, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
53.	GNC (INTL) Bitter Melon Extract Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) Bitter Melon Extract Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Bitter Melon Extract Capsule, needs clarification. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
54.	GNC Senna Capsule	<p>Deferred with final opportunity for the provision of following documents:</p>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Senna Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Senna Capsule, needs clarification. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
55.	GNC COQ-10 200 Softgel Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC COQ-10 200 Softgel Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is COQ-10 200 Softgel Capsule, needs clarification. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
56.	GNC Kids Multivitamin Chewable Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Kids Multivitamin Chewable Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is Kids Multivitamin Chewable Tablet, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
57.	GNC Valerian HP Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Valerian HP Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Valerian HP Capsule , needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
58.	GNC (INTL) COD Liver Oil Softgel capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) COD Liver Oil Softgel capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL COD Liver Oil, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
59.	GNC PN Stress Support Caplets	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC PN Stress Support Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is PN Stress Support Caplets, needs clarification. • Monograph of Magnolia Bark Extract and Phellodendron Bark Extract are required. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.

S.No	Brand name	Decision
(1)	(2)	(3)
60.	GNC Iron Complete Womens Caplets	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Iron Complete Womens Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is Iron Complete Womens Caplets, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.\ • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
61.	GNC Inositol 500 Tablet	Deferred with the final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Inositol 500 Tablet • and brand name given on Exhibit A attached copy of Certificate of Free Sale is Inositol 500 Tablet, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
62.	GNC (INTL) Mega Men 50 Plus Caplet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) Mega Men 50 Plus Caplet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Mega Men 50 Plus Caplet, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
63.	GNC (INTL) Wum 50+ Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) Wum 50+ Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Wum 50+ Tablet, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
64.	GNC Men's Arginmax Caplets	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC Men's Arginmax Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is Men's Arginmax Caplets, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
65.	GNC (INTL) Wum Essentials Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) Wum Essentials Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL Wum Essentials Capsule, needs clarification.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
66.	GNC (INTL) AMP GOLD Thermo Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Brand Name mentioned on Form 5 is GNC (INTL) AMP GOLD Thermo Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL AMP GOLD Thermo Tablet, needs clarification. • Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A. • Manufacturing license of principal manufacturer issued by regulatory body in country of origin duly notarized and counter signed by Embassy of Pakistan, is required.
M/s Diversified Marketing Group (DMG), House # 245, Ground Floor, Saidpur Road, Scheme # 1, Rawalpindi agent of M/s Norel S.A., Pol.Ind.de Valls, Ctra. Pla Santa Maria, 271-273 43800. Valls (Tarragona), Spain (E. No. 00989)		
67.	Anilox PSE-5	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Applied formulation is antioxidant, therefore role of this formulation under SRO 412 is required. • Long term and accelerated stability studies data according to the requirements of Zone IV A are required.
68.	Glymet Mix Plus	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Conversion of percentage strength into unit strength is required. • Long term and accelerated stability studies data according to the requirements of Zone IV A are required.
M/s Metier Wellness Private Limited, located at the address 20, Sector 27, Korangi Industrial Area, Karachi-Pakistan agent of M/s Pharmalink S.L., Avinguda Universital Autonoma, 13, 08290, Cerdanyola del Valles, Barc-elona-Spain (E. No. 00721)		
69.	Easy Sleep Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Melatonin is included in the list of common molecule. • Brand Name mentioned on Free sale certificate, COA and Stability Studies data is Eficaps Sueno while brand name on form 5 is Easy Sleep capsule, needs clarification in this regards.
M/s PDH Laboratories Pvt. Ltd., located at Near Dosaco Chowk, 9.5-Km Sheikhpura Road, District Sheikhpura agent of M/s PT Novell Pharmaceutical Laboratories, located at Jalan Wanaherang No.35, Tlajung Udik, Gunung Putri City, Bogor Province, West Java, Indonesia (E.No. 01115)		
70.	Lithotrip Capsule	Deferred with the final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Valid and Notarized Free sale certificate attested by regulatory body in country of origin and countersigned by the Embassy of Pakistan in country of origin.
M/s Huzaiifa International, Commercial Area, Aziz Bhatti Town, Sargodha agent of M/s Shandong Soocom Animal Remedy Co., Ltd., Xundakang Road No. 666 Agricultural High & New Technology Development Zone of Jinan, China (E. No. 01084)		
71.	Soocom-Acid Oral Solution	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Signed and Stamped Form 5 under SRO 412 is required.
M/s Nutri Tech, 55-C, located at the address Malik Naeem Street, Aitchison Society, Raiwind Road, Lahore agent of M/s Kemin Europa N.V, Toekomstlaan 42, 2200 Herentals, Belgium (Principal manufacturer: M/s Kemin Cavriago SRL, Via Nizzola 5, 42025 – Cavriago (RE) Italy) (E. No. 00986)		
72.	LysiPearl	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Signed and stamped form 5 is required. • Conversion of percentage strength into unit strength is required and per serving dose is also required. • Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.
73.	ButiPeral	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Signed and stamped form 5 is required. • Conversion of percentage strength into unit strength is required and per serving dose is also required. • Role of calcium butyrate under SRO 412 is required. • Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required. • Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.
74.	LysiGem	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Signed and stamped form 5 is required. • Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required. • Furthermore long term stability studies data should be given after every 3 months in first year, every six months in second year and every year thereafter. • Valid Free sale certificate to be attested by concern regulatory body in the country of origin notarized and countersigned by Embassy of Pakistan in country of Origin.
75.	CholiPeral	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Signed and stamped form 5 is required. • Conversion of percentage strength into unit strength is required and per serving dose is also required. • Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required. • Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.
76.	NutriCab	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Signed and stamped form 5 is required. • Justification of Formulation is required. • Conversion of percentage strength into unit strength is required and per serving dose is also required. • required. • Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required. • Furthermore long term stability studies data should be given after every 3 months in first year, every six months in second year and every year thereafter. • Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.
77.	MetiPearl	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> • Signed and stamped form 5 is required. • Conversion of percentage strength into unit strength is required and per serving dose is also required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Long term (according to Zone IV A) and accelerated stability studies data indicating physical and microbiological assay are required. • Valid Free sale certificate to be attested by concern regulatory body in the country of origin, notarized and countersigned by Embassy of Pakistan in country of Origin.
M/s Jacked Nutrition, Shop No. 2 and 3, Ground Floor, Commercial Plot No. 1, Multi Arcade, E-11/1, Islamabad agent of M/s Blade Sport Kft. HU 1055 Budapest, Nyugati square 6, Hungary (Principal Manufacturer M/s Elelmiszteripari Kft., Pinkeret 1, H-9142, Rabapatona, Hungary) (E. No. 01083)		
78.	BLADE Casein (CHOCOLATE) 1816g	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Free sale certificate of Blade casein (Chocolate) is required. • Strength of protein matrix and casein concentrate is required. • Stability studies data of all active ingredients is required.
79.	BLADE Muscle maxx (CHOCOLATE)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Stability studies data of all active ingredients is required.
80.	BLADE Protein Concentrate (CHOCOLATE)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Stability studies data of all active ingredients is required.
81.	BLADE WHEY PROTEIN (CHOCOLATE)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Stability studies data of all active ingredients is required.
M/s Edmark, Shop No. 29, Ground Floor, Noorani Medicine Market, North Napier Road, Karachi agent of M/s Edmark Industries SDN, BHD., No, Jalan BK 1/13, Kinrara Industries Park, 471800 Puchong, Selangor Darul Ehasn, Malaysia (E. No. 01142)		
82.	Edmark's Hawaiian Spirulina Tablet (Chewable)	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required.
83.	Edmark's Bio Elixir Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required.
84.	Edmark's Cafe 73 Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required. • Role of formulation as health product is required.
85.	Edmark's Edmark Cafe Ginseng Coffee Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required. • Role of sugar, Non Dairy Creamer, instant coffee powder as health product are required.
86.	Edmark's Edmark Cafe Powder Black Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required. • Role of formulation as health product is required.
87.	Edmark's Edmark Cafe Troika Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Role of sugar, Non Dairy Creamer, instant coffee powder as health product are required.
88.	Edmark's Edmark Cocollagen Drink Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required.
89.	Edmark's Edmark Splina Liquid Chlorophyll	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required.
90.	Edmark's Edmark MRT Complex Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required. • Role of Low fat milk, chocolate powder and Fructose, Guar Gum as health product are required.
91.	Edmark's Edmark Shake Off Phyto Fiber Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required.
92.	Edmark's Edmark Spiro Sachet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required. • Role of sugar, Non Dairy Creamer, instant coffee powder and brown rice as health product are required.
93.	Edmark Mocha Powder	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and Accelerated stability Studies data indicating chemical and physical assay of each active ingredient along with specified upper and lower limit is required. • Role of Sugar, Non Dairy Creamer, Skim Milk Powder and Cocoa Powder as health product is required.
M/s Macter International Limited, F-216, SITE, Karachi agent of M/s Best Formulation INC. 17758 Rowland Street City of Industry CA 91748, USA (E. No.)		
94.	MAC CBD	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data according to requirements of Zone IV A are required. • Valid and notarized Free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin is required. • It is stated that cannabidiol in the strength of 100mg /ml is registered as a drug in exporting country (USA), in this regards clarification is required w.r.t. cannabidiol oil as health product under SRO 412. • Agency agreement between principal manufacturer i.e. M/s Best Formulation, USA and M/s Macter International, Karachi is required. As one document on the subject "Distributorship, Regulatory, Sales and Marketing agreement" is between M/s Green Releaf LLC, NY, USA and M/s Macter International, Karachi. In this regards, this information is not depicted in form 6.
95.	MAC CBD	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Long term and accelerated stability studies data according to requirements of Zone IV A are required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Valid and notarized Free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin is required. It is stated that cannabidiol in the strength of 100mg /ml is registered as a drug in exporting country (USA), in this regards clarification is required w.r.t. cannabidiol oil as health product under SRO 412. Agency agreement between principal manufacturer i.e. M/s Best Formulation, USA and M/s Macter International, Karachi is required. As one document on the subject "Distributorship, Regulatory, Sales and Marketing agreement" is between M/s Green Releaf LLC, NY, USA and M/s Macter International, Karachi. In this regards, this information is not depicted in form 6.
96.	MAC CBD	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Long term and accelerated stability studies data according to requirements of Zone IV A are required. Valid and notarized Free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin is required. It is stated that cannabidiol in the strength of 100mg /ml is registered as a drug in exporting country (USA), in this regards clarification is required w.r.t. cannabidiol oil as health product under SRO 412. Agency agreement between principal manufacturer i.e. M/s Best Formulation, USA and M/s Macter International, Karachi is required. As one document on the subject "Distributorship, Regulatory, Sales and Marketing agreement" is between M/s Green Releaf LLC, NY, USA and M/s Macter International, Karachi. In this regards, this information is not depicted in form 6.
M/s SHS Nutrition, Shireen Arcade, Mezzanine Floor, Suite No. 3, Plot No. A-41, K.C.H.S.U Block 7/8 Karachi (Principal manufacturer: M/s Shanghai QiangSheng Wanshineng Health Co. Ltd. No. 315 Fengpar Rd, Haiwan Toursim, Fengxin Town, Fengxian District, Shanghai, China (E. No. 0058)		
97.	ActiLife F 50+ Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
98.	Pregnable F Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
99.	Acti-Joint Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required. Glucosamine and Chondroitin Sulphahte are included in list of common molecule.
100.	Pregnable M Tablet	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required
101.	Bonnicare Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
102.	Stimulin Capsule	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
103.	Bonetabl Tablet	<p>Deferred with final opportunity for the provision of following documents:</p>

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
104.	Joggle Box Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required. • Chitosamine and Chondroitin Sulphate is included in the list of common molecule.
105.	ActiLife F Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
106.	Actifile M capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
107.	Actilife M50+ Tablet	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
108.	Proganycare Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Original and valid free sale certificate notarized and countersigned by the Embassy of Pakistan in country of origin is required.
M/s Suas Pharmaceuticals., Suite 338, 3rd Floor, Land Mark Plaza, 5/6 Jail Road, Lahore agent of M/s Natural Fervor Inc., 17801-J Sky Park Circle, Irvine, CA 92614 USA (Principal Manufacturer: M/s Viva Pharmaceutical Inc., 13880 Viking Place, Richmond, British Columbia, Canada) (E. No. 01144)		
109.	Kiditoin Multivitamin Gummy	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Signed and stamped Form 5 under SRO 412 is required. • Long term and Accelerated stability studies data according to requirements of Zone IV A are required. • Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin.
110.	Kiditon Antioxidant Gummy	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Signed and stamped Form 5 under SRO 412 is required. • Long term and Accelerated stability studies data according to requirements of Zone IV A are required. • Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin.
111.	Kiditon Stonger Bones	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Signed and stamped Form 5 under SRO 412 is required. • Long term and Accelerated stability studies data according to requirements of Zone IV A are required. • Valid and notarized free sale certificate attested by the regulatory body in country of origin and countersigned by Embassy of Pakistan in country of Origin.
M/s Peshawar Traders (Pvt) Ltd., 2-5 Mulagori Plaza Bacha Khan Chowak Peshawar agent of M/s Biovet, S.A., C/Luxemburg, 25 Poligon Industrial, 43120 Constanti – Tarragona, Spain (E. No. 00882)		
112.	Alquerfeed Esevital	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Application to be applied on prescribed form 5 under SRO 412(I)/2014. • Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.
113.	Alquernat Livol L	Deferred with final opportunity for the provision of following documents:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Application to be applied on prescribed form 5 under SRO 412(I)/2014. • Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.
114.	Alqueplus Revital	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Application to be applied on prescribed form 5 under SRO 412(I)/2014. • Accelerated and long term stability studies data indicating physical assay and microbiological assay are required. • Formulation contains Glucose as an active ingredient, which is included in the list of common molecule.
115.	Alquernat Zycos L	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Application to be applied on prescribed form 5 under SRO 412(I)/2014. • Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.
116.	Alquermold Natural L	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Application to be applied on prescribed form 5 under SRO 412(I)/2014. • Accelerated and long term stability studies data indicating physical assay and microbiological assay are required.
M/s Genetics Healthcare, 537-A, Sundar Industrial Estate, Lahore agent of M/s BioGrowing Co. Ltd. No. 10666, Songze Rd, Qingpu, Shanghai, 201700, CHINA (E. No. 00103)		
117.	Ezegut capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula. • COA of finished product indicating assay of each probiotic (mentioned in formulation) is required. • Testing specification and characterization of each probiotic is required. • Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin. • Long term and accelerated stability studies data according to requirement of Zone IV A is are required.
118.	Heligut Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula. • COA of finished product indicating assay of each probiotics (mentioned in formulation) is required. • Testing specification and characterization of each probiotics is required. • Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin. • Long term and accelerated stability studies data according to requirement of Zone IV A is are required.
119.	Biolip Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula. • COA of finished product indicating assay of each probiotic (mentioned in formulation) is required. • Testing specification and characterization of each probiotic is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin. Long term and accelerated stability studies data according to requirement of Zone IV A is are required.
120.	Grab Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula. COA of finished product indicating assay of each probiotic (mentioned in formulation) is required. Testing specification and characterization of each probiotic is required. Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin. Long term and accelerated stability studies data according to requirement of Zone IV A is are required.
121.	Sinohale Capsule	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Form 5 to be revised w.r.t strength (enumeration) of each probiotic according to strength given in master formula. COA of finished product indicating assay of each probiotic (mentioned in formulation) is required. Testing specification and characterization of each probiotic is required. Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin. Long term and accelerated stability studies data according to requirement of Zone IV A is are required.
<p align="center">M/s Schazoo SPL Consumer Healthcare, located at the address 71-B, C/2, Gulberg III, Lahore agent of M/s S.I.I.T S.R.L Servizio Internazionale Imballaggi Termosaldanti, Via L. Ariosto, 50/60-20090 Sul Naviglio, Italy (E. No. 00948)</p>		
122.	Duravit Tablet	Deferred with the final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term stability studies data according to requirement of Zone IV A.
<p align="center">M/s Tec Man International., House No. 226, Race Course Road, Westridge No. 1 Rawalpindi agent of M/s Bedson S.A, Las Palmeras 2240, Ruta 8-Km, 47 (1629) La Lonja, Pilar, Buenos Aires, Argentina (E. No. 01029)</p>		
123.	Bedgen 40 SFA concentrate	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> COA of active ingredient and Finished product. Accelerated and long term stability studies data according to requirement of Zone IV A. Free Sale Certificate is required. GMP Certificate is required.
<p align="center">M/s Metier Wellness Private Limited, 20 Sector 27, Korangi Industrial Area, Karachi agent of M/s HC Clover Productos Y Servicios, S.L C/Alicante, 8-10 Arganda del Rey, 28500, Madrid, Spain (E. No. 01049)</p>		
124.	Char Clean Softgel Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Charcoal is included in the list of common molecule.
<p align="center">M/s Ghazi Brothers, located at the address Ghazi House, D-35, KDA Scheme #1, Miran Muhammad Shah Road, Karachi-75350-Pakistan agent of M/s Crown Pacific Biotechnology Pte. Ltd. 38 Penjuru Lane, Singapore 609204 (Veterinary) (E. No. 00720)</p>		
125.	GB Vitalink Feed Grade	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data according to the requirements of Zone IV A are required.
126.	GB Nutrimin Feed Grade	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> Long term and accelerated stability studies data according to the requirements of Zone IV A are required.

S.No (1)	Brand name (2)	Decision (3)
M/s Galaxy Pharma (Pvt) Limited, D-180, Rojhan Street, Block-5, Clifton, Karachi-75600 agent of M/s Lo. Li Pharma International, Roma-00156-VIA dei LUXARDO, 33-VAT.067851002, Italy (E. No. 0056)		
127.	Alfagut Pakistan	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> • COA of active ingredients and finished product is required. • Monograph of Alfa-Lactalbumin is required. • Role of Alfa Lactalbumin as health product under SRO 412 is required. • Valid and Notarized Free sale certificate attested by the regulatory body and countersigned by the Embassy of Pakistan in country of origin. • Long term and accelerated stability studies data according to requirement of Zone IV A is are required. • Pack size is not provided.
M/s K&K Pharmaceutical, Office No. 8, 2nd Floor, Anwar Tower, 99 Shadman Chowk, Lahore agent of M/s Velle B.V. Holland, 56-7882, BA Emenn, The Netherlands (E. No. 01140)		
128.	Velle Hepatone Oral solution	Deferred for following reasons: <ul style="list-style-type: none"> • Signed and stamp form 5 is not provided.
129.	Velle Esel	Deferred for following reasons: <ul style="list-style-type: none"> • Signed and stamp form 5 is not provided.
130.	Velle Bronchomint Oral Solution	Deferred for following reasons: <ul style="list-style-type: none"> • Signed and stamp form 5 is not provided.
131.	Lyzo-Immune-Plus Powder	Deferred for following reasons: <ul style="list-style-type: none"> • Signed and stamp form 5 is not provided.
M/s ACE Biotics, Lahore		
132.	Folic Ace Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Adcok Pharmaceutical (Pvt) Ltd, Lahore		
133.	Chem-Cid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Angel Human Health Nutraceutical, Faisalabad		
134.	Obecease Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
135.	Novocal-D Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
136.	Expel Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
137.	Loflam Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of Vites vinifera extract is required

S.No (1)	Brand name (2)	Decision (3)
138.	Serrix-Ds Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Serratiopeptidase which is in the list of common molecule and deferred till the finalization of policy
139.	Serrix Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Serratiopeptidase which is in the list of common molecule and deferred till the finalization of policy
140.	Novo D Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
141.	Infa-Ad Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
142.	Vitum Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
143.	Osteowax Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Glucosamine and Chondroitin sulphate which is in the list of common molecule and deferred till the finalization of policy
144.	Citilin Oral Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Citocoline which is in the list of common molecule and deferred till the finalization of policy Brand name needs to be changed
145.	Citilin Tabetl	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Citocoline which is in the list of common molecule and deferred till the finalization of policy Brand name needs to be changed
146.	Dormin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Melatonin which is in the list of common molecule and deferred till the finalization of policy Brand name needs to be changed
147.	Dormin Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation contains Melatonin which is in the list of common molecule and deferred till the finalization of policy Brand name needs to be changed
148.	Inosical Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Monograph of calcium lactate gluconate is required Brand name needs to be changed
149.	Crosbery Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
150.	Criscros Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed
151.	Apifas Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Brand name needs to be changed Undertaking notarized regarding content and brand name is required
M/s ARK Laboratories, Hattar		
152.	Vitanex Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Fee submission along with evidence of R and I receiving is required

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Brand name needs to be changed
153.	Olwit Syrup 180MI	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Monograph of fish collagen protein is required • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
154.	Pexil Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Monograph of Lavendula extract and Bacopa monieri ext are required • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
155.	Pexil 120MI Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Monograph of Lavendula extract and Bacopa monieri ext are required • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
156.	Commit Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Monograph of coral calcium is required • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
157.	Commit Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Monograph of coral calcium is required • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
158.	Recco Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
159.	Recco Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Fee submission along with evidence of R and I receiving is required • Brand name needs to be changed
M/s Asfar Healthcare, Kasur		
160.	Simcal-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
161.	Sharbat Sandal	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product

S.No	Brand name	Decision
(1)	(2)	(3)
		application to check its status whether it has been disposed of or otherwise.
162.	D-Bone Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
163.	Apicon Suspensionn	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
164.	Sharbat Gulab	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
165.	Cran Insta Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
166.	Sharbat Badam	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
167.	Sharbat Bazoori	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

M/s Avant Pharmaceutical, Karachi

S.No (1)	Brand name (2)	Decision (3)
168.	Laxazon Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> •The applied formulation contains sennosides A and B which is in the list of common molecule and deferred till the finalization of policy •Properly filled signed and stamped form 3 is required •Brand name needs to be changed
M/s Bio Life Enterprises Nutraceuticals, Rawalpindi		
169.	Pcos-Nil Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Evidence of fee submission is required • Brand name needs to be changed • Revised form 3 w.r.t specification is required
M/s Bio Natural Solution, Islamabad		
170.	Se-Tarzane	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Bio Serve Pharma, Karachi		
171.	Obexa Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
M/s Bio-Med Pharma, Karachi		
172.	Biocid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
M/s Bion Life Sciences, Lahore		
173.	Nutriquil	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Bless Laboratories Pvt. Ltd., Lahore		
174.	C Plus D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
175.	Jovotil Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
176.	Plus D Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No (1)	Brand name (2)	Decision (3)
		preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Burj Healthcare, Karachi		
177.	Well Flour Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> The applied formulation is probiotic preparation and firm doesn't hold Probiotic sachet section Deferred for verification of current GMP status of the firm
178.	Proleaf Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required
179.	Nulac Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required Evidence of fee submission is required The applied formulation contains Sennosides A and B which is in the list of common molecule
180.	Nucal Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required Evidence of fee submission is required
181.	Nuberry Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required
182.	Faab D Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Revised form 3 w.r.t specification of active ingredients is required
183.	Nutacid Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required
184.	Faab Rest Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required
185.	Orocal Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required Evidence of fee submission is required
186.	Numum Sachet	EEC decided to defer the application for enlistment due to following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
187.	Faab Folat Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
188.	Fablux Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required • Evidence of fee submission is required The applied formulation contains SennosidesA and B which is in the list of common molecule
189.	Numin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
190.	Nupro Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation is probiotic preparation and firm doesn't hold Probiotic sachet section • Deferred for verification of current GMP status of the firm
191.	Nuzyme Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Firm uses herbs in crude form while possessing nutraceutical facility
192.	Faab Berry Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
193.	Anvit Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
194.	Cosvit Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Revised form 3 w.r.t specification of active ingredients is required
195.	Eural Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
196.	Orocal Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed • Revised form 3 w.r.t specification of active ingredients is required
197.	Fair Glow Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Deferred for verification of current GMP status of the firm • Brand name needs to be changed

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Revised form 3 w.r.t specification of active ingredients is required
198.	Geritrol Syrup	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required
199.	Geritrol Tablet	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> Deferred for verification of current GMP status of the firm Brand name needs to be changed Revised form 3 w.r.t specification of active ingredients is required
M/s Calgan Phyto Pharma Pvt Ltd, Lahore		
200.	Osteo Best Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
201.	Famfol Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
202.	Ferronate Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
203.	E-Cos Liquid Herbal Ext	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
M/s Cosmo Pharma International Pvt Ltd, Karachi		
204.	C-Plex Gel	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of</p>

S.No (1)	Brand name (2)	Decision (3)
		health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
205.	Piles-X Ointment	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
206.	C-Fair Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
207.	C-Dex Ointment	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
208.	Go-Pain Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Focus & Rulz Healthcare, Islamabad		
209.	Forebone Suspension	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
210.	Forebone Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Glorious Laboratories, Islamabad		
211.	Neurobex Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed

S.No (1)	Brand name (2)	Decision (3)
212.	Brain In Drops	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Monographs of Sage ext,Skullcap ext and Gotu Kola leaves ext are required
213.	Cartin Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed
214.	Calsaint Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
215.	Intel Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
M/s Herbiotics Healthcare, Islamabad		
216.	Female Folic Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is common molecule and deferred till the finalization of policy
M/s Hiranis Pharmaceuticals (Pvt) Limited, Karachi		
217.	Sleapease Tablet 1Mg	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is registered as a drug. Furthermore the applied strength is even higher then the registered drug
M/s Nutrabiotics Nutritional Life Sciences, Peshawar		
218.	Relaxi Max Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Glucosamine sulphate and Chondroitin sulphate which are in the common molecule and deferred till the finalization of policy • Signed form 3 is required
M/s Oasis Pharma, Lahore		
219.	Pro One Tablet	EEC decided to defer the application for enlistment due to following reasons: Brand name needs to be changed
M/s Paksons Neuro, Kabirwala		
220.	Pan-Z Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Glucosamine and Diacrin which is common molecule • Brand name needs to be change
M/s Phytocon International Private Limited, Lahore		
221.	Kalv Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No (1)	Brand name (2)	Decision (3)
		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
222.	Kalv Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
223.	Zeest Aktiv Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
224.	Calix Max Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
M/s Sois Life Sciences, Karachi		
225.	Natalvit Iq Tablet+ Softgel	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Justification and rationality of two dosage forms of different formulation in single product under single name is required
M/s Tahseen Industries, Lahore		
226.	Zinc-Pro Od Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Zinc sulphate as single ingredient which is common molecule
227.	Aerro Lax Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Zinc sulphate as single ingredient which is common molecule
228.	Aerro Lax Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Ferrous sulphate as single ingredient which is common molecule
229.	Coughlax Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
M/s Vida Laboratories, Karachi		
230.	Delon 550Mg Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Fee paid for herbal products • Firm uses herbs in crude form • Confirmation of Herbal Capsule section
231.	Verfew 250Mg Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Fee paid for herbal products • Firm uses herbs in crude form • Confirmation of Herbal Capsule section
232.	Setil 450Mg Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Fee paid for herbal products • Firm uses herbs in crude form • confirmation of Herbal Capsule section

S.No (1)	Brand name (2)	Decision (3)
233.	Turmin Capsule 500Mg	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Fee paid for herbal products and firm uses extract as nutraceutical product Differential fee is required
234.	Estroven Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Fee paid for herbal products and firm uses extract as nutraceutical product Differential fee is required • Brand name needs to be changed
235.	Rikavir Tablet 180Mcg	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Stamped form 3 is required
M/s Whiz Laboratories, Islamabad		
236.	Glutawhiz Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
237.	Stomatize Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Brand name needs to be changed
238.	Memowhiz Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
239.	Memowhiz Syrup	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed
240.	Vizocran Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed • Undertaking notarized regarding content is required
241.	Arthowhiz Tablet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Glucosamine and chondroitin which are common molecule • Brand name needs to be changed
242.	Tener Capsule	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Hyaluronic acid which is common molecule • Brand name needs to be changed


(Ayyaz Ahmad)

Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY**.

MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYY Y
2.								

MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	XYZ Tablet Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's
2.					